Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Transcription factors are believed to have a dominant role in acute myeloid leukemia (AML). This idea is supported by analysis of gene-knockout mice, which uncovered crucial roles of several transcription factors in normal hematopoiesis, and of individuals with leukemia, in whom transcription factors are frequently downregulated or mutated. However, analysis of knockout animals has not shown a direct link between abrogated transcription factors and the pathogenesis of AML. Sfpi1, encoding the lineage-specific transcription factor PU.1, is indispensable for normal myeloid and lymphoid development. We found that mice carrying hypomorphic Sfpi1 alleles that reduce PU.1 expression to 20% of normal levels, unlike mice carrying homo- or heterozygous deletions of Sfpi1, developed AML. Unlike complete or 50% loss, 80% loss of PU.1 induced a precancerous state characterized by accumulation of an abnormal precursor pool retaining responsiveness to G-CSF with disruption of M- and GM-CSF pathways. Malignant transformation was associated with a high frequency of clonal chromosomal changes. Retroviral restoration of PU.1 expression rescued myeloid differentiation of mutant progenitors and AML blasts. These results suggest that tightly graded reduction, rather than complete loss, of a lineage-indispensable transcription factor can induce AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preleukemic states (e.g., MDS), where PU.1 downregulation permits clonal expansion 33-35”
From USP7 sustains hematopoietic stem cell homeostasis partially via PU.1 stabilization (2026) · cites this paper as [33]
In the citing paper
“In mice, a decrease in Pu.1-mediated differentiation gene activation causes leukemia.22”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [22]
In the citing paper
“Studies in murine models of AML with decreased levels of PU.1 showed an elevated expression of c-Myc.28”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [28]
In the citing paper
“A reduction in PU.1 expression and activity is commonly seen in mouse and human cases of AML.[28][29][30]”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [28]
In the citing paper
“Although loss or near-complete loss of the hematopoietic transcription factor PU.1 induces acute myeloid leukemia (AML) in mice”
From Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia (2015) · cites this paper as [9]
19 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617 · cited 1×
“We could not separate mutant progenitors into distinct common myeloid progenitor, myeloid-erythroid progenitor and granulocyte-macrophage progenitor subpopulation”
BackgroundSelf-citationOkuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856 · cited 1×
“Like mice deficient in other transcription factors implicated in human AM”
BackgroundThe c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289 · cited 1×
“F331 Spleen 39,X,-Y[6]/40,idem,+15[2]/41,XY,+15[2]”
Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130
An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination
Meyers, E. N., Lewandoski, M., & Martin, G. R. (1998) · Nature Genetics · doi:10.1038/ng0298-136 · Cited by 1,031 · cited 1×
“We released a FRT -PGK neo - FRT resistance cassette from pK-11 (ref”
MethodZhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“Like mice deficient in other transcription factors implicated in human AM”
BackgroundSelf-citationPabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901
Self-citationReversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Research works printed but not linked: 2
- Iwasaki-Arai, J. et al. C/EBPα deficiency in hematopoiesis induces accumulation of non-malignant myeloblasts mimicking acute myelogenous leukemia. Blood 100, 61a (2002).
- Duprez, E. et al. PU.1 deficiency blocks the production of Common Myeloid and Common Lymphoid Progenitors in both adult and fetal liver myelopoiesis. Blood 100, 61a (2002).
Cited by
Microglia and macrophages in brain homeostasis and disease
Li, Q., & Barres, B. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.125 · Cited by 1,999
The selection and function of cell type-specific enhancers
Heinz, S., Romanoski, C. E., Benner, C., & Glass, C. K. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3949 · Cited by 1,010
Pietras, E. M., Mirantes-Barbeito, C., Fong, S., Loeffler, D., Kovtonyuk, L. V., Zhang, S., Lakshminarasimhan, R., Chin, C. P., Techner, J.-M., Will, B., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3346 · Cited by 689
Transcription factors in myeloid development: balancing differentiation with transformation
Rosenbauer, F., & Tenen, D. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2024 · Cited by 606
Self-citationCabezas-Wallscheid, N., Klimmeck, D., Hansson, J., Lipka, D. B., Reyes, A., Wang, Q., Weichenhan, D., Lier, A., von Paleske, L., Renders, S., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.07.005 · Cited by 589
“Indeed, we found that DMRs coincided with previously identified cis-acting regulatory sites at the Sfpi1 (Rosenbauer et al., 2004) and Gata2 (Gao et al.”
Polycomb group proteins: navigators of lineage pathways led astray in cancer
Bracken, A. P., & Helin, K. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2736 · Cited by 523
DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction
Bröske, A.-M., Vockentanz, L., Kharazi, S., Huska, M. R., Mancini, E., Scheller, M., Kuhl, C., Enns, A., Prinz, M., Jaenisch, R., et al. (2009) · Nature Genetics · doi:10.1038/ng.463 · Cited by 478
Self-citationMapping transcriptomic vector fields of single cells
Qiu, X., Zhang, Y., Martin-Rufino, J. D., Weng, C., Hosseinzadeh, S., Yang, D., Pogson, A. N., Hein, M. Y., Hoi (Joseph) Min, K., Wang, L., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.045 · Cited by 439
“Given the high levels of SPI1 in HSPCs and the fact that knockdown of SPI1 to 20% of its original expression still allows emergence of GMP lineages (Rosenbauer et al., 2004), the low threshold of GATA1 for self-activation and inhibition to SPI1 helps it to compete with SPI1 to generate the”
Iwasaki, H., Somoza, C., Shigematsu, H., Duprez, E. A., Iwasaki-Arai, J., Mizuno, S.-I., Arinobu, Y., Geary, K., Zhang, P., Dayaram, T., et al. (2005) · Blood · doi:10.1182/blood-2005-03-0860 · Cited by 433
Self-citationTranscriptional control of granulocyte and monocyte development
Friedman, A. D. (2007) · Oncogene · doi:10.1038/sj.onc.1210764 · Cited by 427
“…of the PU.1 distal enhancer located at 14 kb results in 20% of normal PU.1 expression and loss of monopoiesis with preservation of granulopoiesis (Rosenbauer et al., 2004); and CRE-mediated deletion of PU.1 in adult mice preserves granulocytes at the expense of monocytes (Dakic et al., 2005).”
BackgroundRojo, R., Raper, A., Ozdemir, D. D., Lefevre, L., Grabert, K., Wollscheid-Lengeling, E., Bradford, B., Caruso, M., Gazova, I., Sánchez, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11053-8 · Cited by 382
Targeting Transcription Factors for Cancer Treatment
Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 352
Laiosa, C. V., Stadtfeld, M., Xie, H., de Andres-Aguayo, L., & Graf, T. (2006) · Immunity · doi:10.1016/j.immuni.2006.09.011 · Cited by 351
The Kruppel‐like factor KLF4 is a critical regulator of monocyte differentiation
Feinberg, M. W., Wara, A. K., Cao, Z., Lebedeva, M. A., Rosenbauer, F., Iwasaki, H., Hirai, H., Katz, J. P., Haspel, R. L., Gray, S., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601824 · Cited by 337
“Interestingly, mice carrying a graded reduction of PU.1 expression to 20% of normal levels develop acute myeloid leukemia (Rosenbauer et al, 2004).”
BackgroundSelf-citationDeletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
Abdel-Wahab, O., Gao, J., Adli, M., Dey, A., Trimarchi, T., Chung, Y. R., Kuscu, C., Hricik, T., Ndiaye-Lobry, D., LaFave, L. M., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131141 · Cited by 322
“In addition, down-regulation of PU.1 expression results in impaired myeloid differentiation (Rosenbauer et al., 2004; Steidl et al., 2006).”
BackgroundDynamic regulation of PU.1 expression in multipotent hematopoietic progenitors
Nutt, S. L., Metcalf, D., D'Amico, A., Polli, M., & Wu, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041535 · Cited by 325
“Deletion of a distal enhancer 14-kb upstream of the start of transcription was recently shown to reduce expression to 20% that of wildtype cells (9).”
BackgroundAbrogation of nuclear receptors Nr4a3 andNr4a1 leads to development of acute myeloid leukemia
Mullican, S. E., Zhang, S., Konopleva, M., Ruvolo, V., Andreeff, M., Milbrandt, J., & Conneely, O. M. (2007) · Nature Medicine · doi:10.1038/nm1579 · Cited by 324
PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis
Dakic, A., Metcalf, D., Di Rago, L., Mifsud, S., Wu, L., & Nutt, S. L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050075 · Cited by 297
“1 is an important tumor suppressor in murine, and possibly human, AML (11, 12).”
BackgroundInfluentialmiR‐155: an ancient regulator of the immune system
Vigorito, E., Kohlhaas, S., Lu, D., & Leyland, R. (2013) · Immunological Reviews · doi:10.1111/imr.12057 · Cited by 293
Carotta, S., Dakic, A., D'Amico, A., Pang, S. H. M., Greig, K. T., Nutt, S. L., & Wu, L. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.005 · Cited by 279
“1 is critical for hematopoietic cell-fate determination and to suppress leukemia (Anderson et al., 2002; Bakri et al., 2005; Dahl et al., 2003; DeKoter and Singh, 2000; Laiosa et al., 2006; Rosenbauer et al., 2004; Ye et al., 2005).”
BackgroundInfluentialA microRNA expression signature of osteoclastogenesis
Sugatani, T., Vacher, J., & Hruska, K. A. (2011) · Blood · doi:10.1182/blood-2010-10-311415 · Cited by 275
Positive Feedback Between PU.1 and the Cell Cycle Controls Myeloid Differentiation
Kueh, H. Y., Champhekar, A., Nutt, S. L., Elowitz, M. B., & Rothenberg, E. V. (2013) · Science · doi:10.1126/science.1240831 · Cited by 273
“In choosing an performance criterion with which to compare these two systems, we surmised that maintaining a stable slow-dividing differentiated state amid noisy gene expression may be an important functional objective of the system, as failure to do so can result in a differentiation arrest and leukemic transformatio…”
Choudhary, C., Schwäble, J., Brandts, C., Tickenbrock, L., Sargin, B., Kindler, T., Fischer, T., Berdel, W. E., Müller-Tidow, C., & Serve, H. (2005) · Blood · doi:10.1182/blood-2004-07-2942 · Cited by 263
DETERMINANTS OF LYMPHOID-MYELOID LINEAGE DIVERSIFICATION
Laiosa, C. V., Stadtfeld, M., & Graf, T. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090742 · Cited by 259
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis.
Huang, G., Zhang, P., Hirai, H., Elf, S., Yan, X., Chen, Z., Koschmieder, S., Okuno, Y., Dayaram, T., Growney, J. D., et al. (2008) · Nature Genetics · doi:10.1038/ng.2007.7 · Cited by 259
Self-citationInterrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing
Li, K., Liu, Y., Cao, H., Zhang, Y., Gu, Z., Liu, X., Yu, A., Kaphle, P., Dickerson, K. E., Ni, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14362-5 · Cited by 251
Takahashi, S. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-13 · Cited by 241
“1 expression to 20% of the normal level, developed AML [57].”
BackgroundTranscriptional networks in developing and mature B cells
Matthias, P., & Rolink, A. G. (2005) · Nature Reviews Immunology · doi:10.1038/nri1633 · Cited by 238
“1 gene, show a block in early myeloid-cell differentiation and an accumulation of immature cells, which eventually leads to the development of acute myeloid leukaemi”
BackgroundYamazaki, H., Suzuki, M., Otsuki, A., Shimizu, R., Bresnick, E. H., Engel, J. D., & Yamamoto, M. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.008 · Cited by 242
“In the CD34highFlt3 cells from the 3q21q26 mice, the abundance of Meis1, Gata2, Pbx1, and p57 gene transcripts, which are all highly expressed in LT-HSCs, had largely decreased; in contrast, we detected high levels of PU.1.”
BackgroundInfluentialRosenbauer, F., Owens, B. M., Yu, L., Tumang, J. R., Steidl, U., Kutok, J. L., Clayton, L. K., Wagner, K., Scheller, M., Iwasaki, H., et al. (2006) · Nature Genetics · doi:10.1038/ng1679 · Cited by 237
Self-citationMOZ is essential for maintenance of hematopoietic stem cells
Katsumoto, T., Aikawa, Y., Iwama, A., Ueda, S., Ichikawa, H., Ochiya, T., & Kitabayashi, I. (2006) · Genes & Development · doi:10.1101/gad.1393106 · Cited by 222
“Recent studies have indicated that mice carrying hypomorphic PU.1 alleles in which PU.1 expression is decreased to 20% of wild-type levels develop acute myeloid leukemia (Rosenbauer et al. 2004).”
BackgroundInfluentialEarly myeloid lineage choice is not initiated by random PU.1 to GATA1 protein ratios
Hoppe, P. S., Schwarzfischer, M., Loeffler, D., Kokkaliaris, K. D., Hilsenbeck, O., Moritz, N., Endele, M., Filipczyk, A., Gambardella, A., Ahmed, N., et al. (2016) · Nature · doi:10.1038/nature18320 · Cited by 206
Dysregulation of the C/EBPα Differentiation Pathway in Human Cancer
Koschmieder, S., Halmos, B., Levantini, E., & Tenen, D. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.9812 · Cited by 212
Self-citationMartinez-Nunez, R. T., Louafi, F., Friedmann, P. S., & Sanchez-Elsner, T. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.011601 · Cited by 213
Mueller, B. U., Pabst, T., Fos, J., Petkovic, V., Fey, M. F., Asou, N., Buergi, U., & Tenen, D. G. (2006) · Blood · doi:10.1182/blood-2005-07-3068 · Cited by 207
Self-citationGATA1 in normal and malignant hematopoiesis
Crispino, J. D. (2005) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2004.11.002 · Cited by 199
Inferring regulatory element landscapes and transcription factor networks from cancer methylomes
Yao, L., Shen, H., Laird, P. W., Farnham, P. J., & Berman, B. P. (2015) · Genome Biology · doi:10.1186/s13059-015-0668-3 · Cited by 198
“Since there are no available normal tissues for acute myeloid leukemia (LAML) and glioblastoma multiforme (GBM) in TCGA, we also downloaded Infinium HM450K DNA methylation data from publicly available sources as normal tissue controls for these two cancer types.”
BackgroundInfluentialSpooner, C. J., Cheng, J. X., Pujadas, E., Laslo, P., & Singh, H. (2009) · Immunity · doi:10.1016/j.immuni.2009.07.011 · Cited by 188
“This resembled the accumulation of similar myeloid precursors in the bone marrow of mice in which PU.1 expression is reduced by targeting an upstream distal enhancer (Rosenbauer et al., 2004).”
BackgroundInfluentialPtasinska, A., Assi, S. A., Mannari, D., James, S. R., Williamson, D., Dunne, J., Hoogenkamp, M., Wu, M., Care, M., McNeill, H., et al. (2012) · Leukemia · doi:10.1038/leu.2012.49 · Cited by 184
Self-citationThe role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis
Burda, P., Laslo, P., & Stopka, T. (2010) · Leukemia · doi:10.1038/leu.2010.104 · Cited by 184
Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells
Steidl, U., Rosenbauer, F., Verhaak, R. G. W., Gu, X., Ebralidze, A., Otu, H. H., Klippel, S., Steidl, C., Bruns, I., Costa, D. B., et al. (2006) · Nature Genetics · doi:10.1038/ng1898 · Cited by 184
Self-citationEbralidze, A. K., Guibal, F. C., Steidl, U., Zhang, P., Lee, S., Bartholdy, B., Jorda, M. A., Petkova, V., Rosenbauer, F., Huang, G., et al. (2008) · Genes & Development · doi:10.1101/gad.1654808 · Cited by 176
“1 gene locus homology regions: the URE (H1 + H2), removed by homologous recombination (Rosenbauer et al. 2004), proximal promoter (PrPr), and H3; initiation sites and orientation of the sense (long white arrow) and”
BackgroundResultInfluentialSelf-citationLichtinger, M., Ingram, R., Hannah, R., Müller, D., Clarke, D., Assi, S. A., Lie-A-Ling, M., Noailles, L., Vijayabaskar, M. S., Wu, M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.275 · Cited by 180
“Such mice are prone to develop leukaemia (Rosenbauer et al , 2004; Huang et al , 2008).”
Self-citationHierarchical Differentiation of Myeloid Progenitors Is Encoded in the Transcription Factor Network
Krumsiek, J., Marr, C., Schroeder, T., & Theis, F. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022649 · Cited by 179
“In addition, many of the genes included in the model are known to be involved in malignant cell transformations during hematopoiesis [21,22].”
BackgroundPotential Autoregulation of Transcription Factor PU.1 by an Upstream Regulatory Element
Okuno, Y., Huang, G., Rosenbauer, F., Evans, E. K., Radomska, H. S., Iwasaki, H., Akashi, K., Moreau-Gachelin, F., Li, Y., Zhang, P., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.7.2832-2845.2005 · Cited by 174
“Finally, “knockdown” mice in which PU.1 expression in the bone marrow was decreased to 20% of wild-type levels all develop a block in macrophage and B-cell development, genomic instability, and acute myeloid leukemia (AML) (53).”
BackgroundInfluentialSelf-citationRoth, M., Will, B., Simkin, G., Narayanagari, S., Barreyro, L., Bartholdy, B., Tamari, R., Mitsiades, C. S., Verma, A., & Steidl, U. (2012) · Blood · doi:10.1182/blood-2011-12-399667 · Cited by 164
Wang, K., Wang, P., Shi, J., Zhu, X., He, M., Jia, X., Yang, X., Qiu, F., Jin, W., Qian, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.045 · Cited by 162
Staber, P. B., Zhang, P., Ye, M., Welner, R. S., Nombela-Arrieta, C., Bach, C., Kerenyi, M., Bartholdy, B. A., Zhang, H., Alberich-Jordà, M., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.01.007 · Cited by 158
“To generate mutant PU.1ki/ki mice, we used the pPNT (–14 kb URE)-targeting vector (Rosenbauer et al., 2004) and introduced a GGAA-to-TCGC mutation by site-directed mutagenesis (Okuno et al., 2005).”
BackgroundMethodResultInfluentialSelf-citationPU.1 regulates Alzheimer’s disease-associated genes in primary human microglia
Rustenhoven, J., Smith, A. M., Smyth, L. C., Jansson, D., Scotter, E. L., Swanson, M. E. V., Aalderink, M., Coppieters, N., Narayan, P., Handley, R., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0277-1 · Cited by 155
Greif, P. A., Dufour, A. M., Konstandin, N. P., Ksienzyk, B., Zellmeier, E., Tizazu, B., Sturm, J., Benthaus, T., Herold, T., Yaghmaie, M., et al. (2012) · Blood · doi:10.1182/blood-2012-01-403220 · Cited by 175
Rosmarin, A. G., Yang, Z., & Resendes, K. K. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.08.015 · Cited by 121
“The additional genetic abnormalities that transform the apparent preleukemic state to overt AML are not yet well defined, although amplification of c-myc was found in four of seven mice [154].”
BackgroundMYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia
Vargova, K., Curik, N., Burda, P., Basova, P., Kulvait, V., Pospisil, V., Savvulidi, F., Kokavec, J., Necas, E., Berkova, A., et al. (2011) · Blood · doi:10.1182/blood-2010-05-285064 · Cited by 144
Epigenetic Modification of CCAAT/Enhancer Binding Protein α Expression in Acute Myeloid Leukemia
Hackanson, B., Bennett, K. L., Brena, R. M., Jiang, J., Claus, R., Chen, S.-S., Blagitko-Dorfs, N., Maharry, K., Whitman, S. P., Schmittgen, T. D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0483 · Cited by 140
Cook, W. D., McCaw, B. J., Herring, C., John, D. L., Foote, S. J., Nutt, S. L., & Adams, J. M. (2004) · Blood · doi:10.1182/blood-2004-06-2234 · Cited by 140
The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity
Liu, Y., Cheney, M. D., Gaudet, J., Chruszcz, M., Lukasik, S. M., Sugiyama, D., Lary, J. W., Cole, J. L., Dauter, Z., Minor, W., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.012 · Cited by 153
“Reductions in PU.1 dosage were recently shown to cause an accumulation of c-kit+ hematopoietic precursors in bone marrow, and predisposed mice to acute myeloid leukemia and T cell lymphoma (Rosenbauer et al., 2004, 2006).”
Transcriptional and Epigenetic Regulation of Microglia in Health and Disease
Yeh, H., & Ikezu, T. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.11.004 · Cited by 135
“1 for the expression of essential cell survival receptors [28].”
BackgroundNF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia
Gerloff, D., Grundler, R., Wurm, A. A., Bräuer-Hartmann, D., Katzerke, C., Hartmann, J.-U., Madan, V, Müller-Tidow, C., Duyster, J., Tenen, D. G., et al. (2015) · Leukemia · doi:10.1038/leu.2014.231 · Cited by 135
Self-citationSite-specific DNA methylation by a complex of PU.1 and Dnmt3a/b
Suzuki, M., Yamada, T., Kihara-Negishi, F., Sakurai, T., Hara, E., Tenen, D. G., Hozumi, N., & Oikawa, T. (2006) · Oncogene · doi:10.1038/sj.onc.1209272 · Cited by 132
“Overexpression and graded reduction of PU.1 induce erythroleukemia and myeloid leukemia in mice, respectively (Moreau-Gachelin et al., 1996; Rosenbauer et al., 2004).”
BackgroundSelf-citationTwo distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells
Leddin, M., Perrod, C., Hoogenkamp, M., Ghani, S., Assi, S., Heinz, S., Wilson, N. K., Follows, G., Schönheit, J., Vockentanz, L., et al. (2011) · Blood · doi:10.1182/blood-2010-08-302976 · Cited by 131
“Plat-E cells were used for viral supernatant production as described.(9) URE and URE cell lines were incubated with retroviral supernatants derived from a murine stem cell virus-based tamoxifen-inducible C/EBPα-ERTGFP construct (gift from J.”
BackgroundMethodInfluentialSelf-citationCooperating cancer-gene identification through oncogenic-retrovirus–induced insertional mutagenesis
Du, Y., Spence, S. E., Jenkins, N. A., & Copeland, N. G. (2005) · Blood · doi:10.1182/blood-2004-12-4840 · Cited by 133
HOXA10 is a critical regulator for hematopoietic stem cells and erythroid/megakaryocyte development
Magnusson, M., Brun, A. C. M., Miyake, N., Larsson, J. T., Ehinger, M., Björnsson, J. M., Wutz, A., Sigvardsson, M., & Karlsson, S. (2007) · Blood · doi:10.1182/blood-2006-10-054676 · Cited by 142
Will, B., Vogler, T. O., Narayanagari, S., Bartholdy, B., Todorova, T. I., da Silva Ferreira, M., Chen, J., Yu, Y., Mayer, J., Barreyro, L., et al. (2015) · Nature Medicine · doi:10.1038/nm.3936 · Cited by 127
PU.1 Level-Directed Chromatin Structure Remodeling at the Irf8 Gene Drives Dendritic Cell Commitment
Schönheit, J., Kuhl, C., Gebhardt, M. L., Klett, F. F., Riemke, P., Scheller, M., Huang, G., Naumann, R., Leutz, A., Stocking, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.007 · Cited by 127
“(G) qRT-PCR of Irf8 and PU.1 mRNA expression in FACS sorted Lin Sca1 c-kit+ myeloid progenitors isolated from the BM of mice with a deleted upstream regulatory element (URE) of the PU.1 gene (Rosenbauer et al., 2004).”
BackgroundMethodInfluentialSelf-citationGuibal, F. C., Alberich-Jorda, M., Hirai, H., Ebralidze, A., Levantini, E., Di Ruscio, A., Zhang, P., Santana-Lemos, B. A., Neuberg, D., Wagers, A. J., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182071 · Cited by 126
Self-citationGraded repression of PU.1/Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate
Chou, S. T., Khandros, E., Bailey, L. C., Nichols, K. E., Vakoc, C. R., Yao, Y., Huang, Z., Crispino, J. D., Hardison, R. C., Blobel, G. A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-207944 · Cited by 110
Macrophage development from HSCs requires PU.1-coordinated microRNA expression
Ghani, S., Riemke, P., Schönheit, J., Lenze, D., Stumm, J., Hoogenkamp, M., Lagendijk, A., Heinz, S., Bonifer, C., Bakkers, J., et al. (2011) · Blood · doi:10.1182/blood-2011-02-335141 · Cited by 123
Self-citationGenome organizing function of SATB1 in tumor progression
Kohwi-shigematsu, T., Poterlowicz, K., Ordinario, E., Han, H., Botchkarev, V. A., & Kohwi, Y. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.06.009 · Cited by 123
Mohr, S., Doebele, C., Comoglio, F., Berg, T., Beck, J., Bohnenberger, H., Alexe, G., Corso, J., Ströbel, P., Wachter, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.001 · Cited by 127
“On the other hand, graded reduction of PU.1 levels, not ablation of PU.1, has been identified as amechanism of leukemic transformation in both human and mouse model systems (Rosenbauer et al., 2004, 2005; Will et al., 2015).”
Hoogenkamp, M., Lichtinger, M., Krysinska, H., Lancrin, C., Clarke, D., Williamson, A., Mazzarella, L., Ingram, R., Jorgensen, H., Fisher, A., et al. (2009) · Blood · doi:10.1182/blood-2008-11-191890 · Cited by 121
Self-citationPharmacological inhibition of the transcription factor PU.1 in leukemia
Antony-Debré, I., Paul, A., Leite, J., Mitchell, K., Kim, H. M., Carvajal, L. A., Todorova, T. I., Huang, K., Kumar, A., Farahat, A. A., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92504 · Cited by 120
“1 URE+/–Msh2–/– leukemia cells (17, 18) were cul-”
BackgroundInfluentialCusan, M., Cai, S. F., Mohammad, H. P., Krivtsov, A. V., Chramiec, A. G., Loizou, E., Witkin, M. D., Smitheman, K. N., Tenen, D. G., Ye, M., et al. (2018) · Blood · doi:10.1182/blood-2017-09-807024 · Cited by 128
Self-citationC/EBPα binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment
Yeamans, C., Wang, D., Paz-Priel, I., Torbett, B. E., Tenen, D. G., & Friedman, A. D. (2007) · Blood · doi:10.1182/blood-2007-03-080291 · Cited by 118
Self-citationGu, X., Ebrahem, Q., Mahfouz, R. Z., Hasipek, M., Enane, F., Radivoyevitch, T., Rapin, N., Przychodzen, B., Hu, Z., Balusu, R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97117 · Cited by 115
Porse, B. T., Bryder, D., Theilgaard-Mönch, K., Hasemann, M. S., Anderson, K., Damgaard, I., Jacobsen, S. E. W., & Nerlov, C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050067 · Cited by 117
“1 regulatory sequences that significantly lower its expression develop AML (18).”
BackgroundInfluentialXu, D., Liu, X., Yu, W.-M., Meyerson, H. J., Guo, C., Gerson, S. L., & Qu, C.-K. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110450 · Cited by 115
“Mac-1+/c-Kit+ my- eloblasts (Cozzio et al., 2003; So et al., 2003; Rosenbauer et al., 2004; Kirstetter et al., 2008) were >20% in the BM (Fig.”
BackgroundSteidl, U., Steidl, C., Ebralidze, A., Chapuy, B., Han, H.-J., Will, B., Rosenbauer, F., Becker, A., Wagner, K., Koschmieder, S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30525 · Cited by 114
Self-citationShimizu, R., Engel, J. D., & Yamamoto, M. P. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2348 · Cited by 124
“1 , additional genetic hit(s) in immature progenitor populations seems to be required for the onset of leukaemi”
BackgroundC/EBPα in normal and malignant myelopoiesis
Friedman, A. D. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1764-6 · Cited by 101
“1 −14 kb enhancer uniformly develop AML by 6 months [102].”
BackgroundMüller‐Tidow, C., Klein, H., Hascher, A., Isken, F., Tickenbrock, L., Thoennissen, N. H., Singh, S. A., Tschanter, P., Disselhoff, C., Wang, Y., et al. (2010) · Blood · doi:10.1182/blood-2009-09-240978 · Cited by 115
The miR-155–PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation
Lu, D., Nakagawa, R., Lazzaro, S., Staudacher, P., Abreu-Goodger, C., Henley, T., Boiani, S., Leyland, R., Galloway, A., Andrews, S., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140338 · Cited by 97
“…manner to regulate gene expression in many cell lineages (Laslo et al., 2006; Carotta et al., 2010a), and several animal models expressing variable amounts of PU.1 have altered hematopoiesis (Rosenbauer et al., 2004; Dakic et al., 2005; Iwasaki et al., 2005; Houston et al., 2007).”
BackgroundTranscriptional dysregulation during myeloid transformation in AML
Pabst, T., & Mueller, B. U. (2007) · Oncogene · doi:10.1038/sj.onc.1210765 · Cited by 120
“1 expression and subsequently developed AML (and lymphomas) (Rosenbauer et al., 2004).”
BackgroundJin, H., Li, L., Xu, J., Zhen, F., Zhu, L., Liu, P. P., Zhang, M., Zhang, W., & Wen, Z. (2012) · Blood · doi:10.1182/blood-2011-12-398362 · Cited by 103
Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia
Antony‐Debré, I., Manchev, V. T., Balayn, N., Bluteau, D., Tomowiak, C., Legrand, C., Langlois, T., Bawa, O., Tosca, L., Tachdjian, G., et al. (2014) · Blood · doi:10.1182/blood-2014-06-585513 · Cited by 111
PU.1: A crucial and versatile player in hematopoiesis and leukemia
Kastner, P., & Chan, S. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.01.026 · Cited by 101
Guo, H. W., Ma, O., Speck, N. A., & Friedman, A. D. (2012) · Blood · doi:10.1182/blood-2011-12-397091 · Cited by 107
Effect of transcription-factor concentrations on leukemic stem cells
Rosenbauer, F., Koschmieder, S., Steidl, U., & Tenen, D. G. (2005) · Blood · doi:10.1182/blood-2005-02-0717 · Cited by 98
Self-citationVisualizing PU.1 activity during hematopoiesis
Back, J., Allman, D., Chan, S., & Kastner, P. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.12.010 · Cited by 97
“1 in myeloid cells also block differentiation and cause myeloid leukemias [2], or regulate macrophage vs neutrophil cell fate [3].”
BackgroundReduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice
Ramirez-Herrick, A. M., Mullican, S. E., Sheehan, A. M., & Conneely, O. M. (2011) · Blood · doi:10.1182/blood-2010-02-267906 · Cited by 96
C/EBPα: A tumour suppressor in multiple tissues?
Schuster, M. B., & Porse, B. T. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.02.003 · Cited by 99
C/EBPα and the pathophysiology of acute myeloid leukemia
Mueller, B. U., & Pabst, T. (2005) · Current Opinion in Hematology · doi:10.1097/01.moh.0000190110.08156.96 · Cited by 112
Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia
Metcalf, D., Dakic, A., Mifsud, S., Di Rago, L., Wu, L., & Nutt, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510616103 · Cited by 95
The RUNX1–PU.1 axis in the control of hematopoiesis
Imperato, M. R., Cauchy, P., Obier, N., & Bonifer, C. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1762-8 · Cited by 94
“1 expression induces a premalignant state that is associated with a high frequency of chromosomal rearrangements, leading to the AML development [101].”
BackgroundMyocyte enhancer factor 2C in hematopoiesis and leukemia
Canté-Barrett, K., Pieters, R., & Meijerink, J. P. P. (2013) · Oncogene · doi:10.1038/onc.2013.56 · Cited by 103
Surprising new roles for PU.1 in the adaptive immune response
Carotta, S., Wu, L., & Nutt, S. L. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00955.x · Cited by 93
“1 expression, but still result in viable adult mice (14, 15, 17, 18).”
BackgroundInfluentialPospisil, V., Vargova, K., Kokavec, J., Rybarova, J., Savvulidi, F., Jonasova, A., Necas, E., Zavadil, J., Laslo, P., & Stopka, T. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.317 · Cited by 93
“This notion is supported by the finding that ectopic expression of EGR2 inhibits miR-17-92 levels in AML blast cells and HL60 AML cell line and by our unpublished observation, that PU.1 hypomorphic mouse (Rosenbauer et al, 2004), developing AML has upregulated miR-17-92 cluster.”
BackgroundPU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress
Chavez, J. S., Rabe, J. L., Loeffler, D., Higa, K. C., Hernandez, G., Mills, T. S., Ahmed, N., Gessner, R. L., Ke, Z., Idler, B. M., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201169 · Cited by 91
Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia
McKenzie, M. D., Ghisi, M., Oxley, E. P., Ngo, S., Cimmino, L., Esnault, C., Liu, R., Salmon, J. M., Bell, C. C., Ahmed, N., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.07.001 · Cited by 91
Maximal STAT5-Induced Proliferation and Self-Renewal at Intermediate STAT5 Activity Levels
Wierenga, A. T. J., Vellenga, E., & Schuringa, J. J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01025-08 · Cited by 103
“1 levels was shown to be highly leukemogenic (42).”
BackgroundSingle-molecule imaging of transcription dynamics in somatic stem cells
Wheat, J. C., Sella, Y., Willcockson, M., Skoultchi, A. I., Bergman, A., Singer, R. H., & Steidl, U. (2020) · Nature · doi:10.1038/s41586-020-2432-4 · Cited by 88
JunB: a paradigm for Jun family in immune response and cancer
Ren, F., Cai, X. T., Yao, Y., & Fang, G.-Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1222265 · Cited by 96
“1 in bone marrow by 80%, resulting in the occurrence of acute myeloid leukemia (AML) in mice (Rosenbauer et al., 2004; Rosenbauer et al., 2005).”
Metadata
- Authors
- Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Dartmouth College (US)
- Corresponding author
- Tenen, Daniel G
- ORCID
- Venue
- Nature Genetics
- Published
- 2004-05-16
- Volume
- 36
- Issue
- 6
- Pages
- 624-630
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2060618743
- Cited by
- 506
- References
- 28
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 11 · 2023: 21 · 2022: 10 · 2021: 25 · 2020: 13 · 2019: 22 · 2018: 25 · 2017: 24 · 2016: 19 · 2015: 18 · 2014: 27 · 2013: 36 · 2012: 28
- FWCI
- 20.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Funders
- Dartmouth College
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- National Cancer Institute (P30CA023108)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- acute myeloid leukemia, PU.1, transcription factors, hypomorphic allele, myeloid development, myeloid differentiation, leukemogenesis
- MeSH terms
- Proto-Oncogene Protein Spi-1, Animals, Bone Marrow, Hematopoiesis, Humans, Karyotyping, Mice, Inbred C57BL, Mice, Mutant Strains, Mice, Transgenic, Proto-Oncogene Proteins, Spleen, Leukemia, Myeloid, Acute, Trans-Activators, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.